Cedric H Bien-Gund1, Joshua I Ho2, Elizabeth F Bair3, Noora Marcus3, Rebekah Ji Choi3, Zsofia Szep4, Amy Althoff4, Florence M Momplaisir1, Harsha Thirumurthy3. 1. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and. 4. Partnership Comprehensive Care Practice, Drexel University College of Medicine, Philadelphia, PA.
Abstract
BACKGROUND: Interventions to promote medication adherence and viral suppression are needed among HIV-positive individuals. We aimed to determine the feasibility, acceptability, and preliminary impact of daily financial incentives linked to real-time adherence monitoring among treatment-experienced individuals. METHODS: At an HIV clinic in Philadelphia, we conducted a pilot randomized trial among treatment-experienced HIV-positive adults with unsuppressed viral loads (>400 copies/mL). Participants randomized to the intervention group were eligible for daily lottery-based financial rewards dependent on antiretroviral therapy (ART) adherence, measured by a wireless-enabled electronic pill bottle. Participants also received a financial incentive for achieving viral suppression at 3 months. The control group received the standard of care. We measured acceptance and feasibility through follow-up survey at 3 months, viral suppression at 3 months, and adherence. RESULTS: Among 29 participants, 28 (93%) completed 3-month follow-up, and 24 (83%) completed a 3-month laboratory visit. Electronic pill bottles were highly acceptable to participants, with most strongly agreeing that they worked well, were reliable, and easy to use. Among those who received the intervention, 77% were very satisfied with their experience. Among those who completed the 3-month laboratory visit, viral suppression was achieved by 40% in the intervention group and 29% in the control group. ART adherence ≥80% was achieved by 36% and 25% in the intervention and control groups, respectively. CONCLUSIONS: Daily financial incentives coupled with real-time adherence monitoring are a promising strategy to support ART adherence among HIV-positive individuals who are not virally suppressed. This novel approach warrants testing in a larger trial.
BACKGROUND: Interventions to promote medication adherence and viral suppression are needed among HIV-positive individuals. We aimed to determine the feasibility, acceptability, and preliminary impact of daily financial incentives linked to real-time adherence monitoring among treatment-experienced individuals. METHODS: At an HIV clinic in Philadelphia, we conducted a pilot randomized trial among treatment-experienced HIV-positive adults with unsuppressed viral loads (>400 copies/mL). Participants randomized to the intervention group were eligible for daily lottery-based financial rewards dependent on antiretroviral therapy (ART) adherence, measured by a wireless-enabled electronic pill bottle. Participants also received a financial incentive for achieving viral suppression at 3 months. The control group received the standard of care. We measured acceptance and feasibility through follow-up survey at 3 months, viral suppression at 3 months, and adherence. RESULTS: Among 29 participants, 28 (93%) completed 3-month follow-up, and 24 (83%) completed a 3-month laboratory visit. Electronic pill bottles were highly acceptable to participants, with most strongly agreeing that they worked well, were reliable, and easy to use. Among those who received the intervention, 77% were very satisfied with their experience. Among those who completed the 3-month laboratory visit, viral suppression was achieved by 40% in the intervention group and 29% in the control group. ART adherence ≥80% was achieved by 36% and 25% in the intervention and control groups, respectively. CONCLUSIONS: Daily financial incentives coupled with real-time adherence monitoring are a promising strategy to support ART adherence among HIV-positive individuals who are not virally suppressed. This novel approach warrants testing in a larger trial.
Authors: Kevin G Volpp; Andrea B Troxel; Mark V Pauly; Henry A Glick; Andrea Puig; David A Asch; Robert Galvin; Jingsan Zhu; Fei Wan; Jill DeGuzman; Elizabeth Corbett; Janet Weiner; Janet Audrain-McGovern Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Cristian Pop-Eleches; Harsha Thirumurthy; James P Habyarimana; Joshua G Zivin; Markus P Goldstein; Damien de Walque; Leslie MacKeen; Jessica Haberer; Sylvester Kimaiyo; John Sidle; Duncan Ngare; David R Bangsberg Journal: AIDS Date: 2011-03-27 Impact factor: 4.177
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Kevin G Volpp; Leslie K John; Andrea B Troxel; Laurie Norton; Jennifer Fassbender; George Loewenstein Journal: JAMA Date: 2008-12-10 Impact factor: 56.272
Authors: Lora L Sabin; Mary Bachman DeSilva; Davidson H Hamer; Keyi Xu; Jianbo Zhang; Tao Li; Ira B Wilson; Christopher J Gill Journal: AIDS Behav Date: 2010-06
Authors: Jessica E Haberer; Robert Baijuka; John Bosco Tumuhairwe; Edna B Tindimwebwa; James Tinkamanyire; Ellyk Tuhanamagyezi; Lawrence Musoke; Lindsey E Garrison; Marisa DelSignore; Nicholas Musinguzi; Stephen Asiimwe Journal: Front Digit Health Date: 2022-07-22
Authors: Alexsandra Andrawis; James Tapa; Ivo Vlaev; Daniel Read; Kelly Ann Schmidtke; Eric P F Chow; David Lee; Christopher K Fairley; Jason J Ong Journal: Curr HIV/AIDS Rep Date: 2022-08-05 Impact factor: 5.495